CG
JAZZ icon

Cutler Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cutler Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,100
Closed -$2K – 5724
2021
Q3 		$2K Hold
25,100
– – ﹤0.01% 5030
2021
Q2 		$1K Buy
+25,100
New +$4.35M ﹤0.01% 5324
2020
Q4 		– Sell
-6,100
Closed -$4K – 5148
2020
Q3 		$4K Buy
6,100
+1,500
+33% +$186K ﹤0.01% 3662
2020
Q2 		$15K Buy
+4,600
New +$509K ﹤0.01% 2587
2018
Q4 		– Sell
-900
Closed -$28K – 4264
2018
Q3 		$28K Buy
+900
New +$155K ﹤0.01% 2028
2017
Q3 		– Sell
-11,300
Closed -$24K – 6260
2017
Q2 		$24K Sell
11,300
-33,300
-75% -$5.09M ﹤0.01% 3231
2017
Q1 		$56K Buy
44,600
+23,800
+114% +$3.1M ﹤0.01% 2301
2016
Q4 		$93K Buy
20,800
+7,600
+58% +$847K ﹤0.01% 1966
2016
Q3 		$560K Buy
13,200
+700
+6% +$94.4K 0.03% 550
2016
Q2 		$357K Sell
12,500
-15,200
-55% -$2.24M 0.02% 767
2016
Q1 		$517K Buy
27,700
+2,200
+9% +$274K 0.03% 512
2015
Q4 		$387K Buy
+25,500
New +$3.53M 0.02% 757

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cutler Group's JAZZ Position: Q1 2023 in Review

Cutler Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 100 shares — an estimated $15K sold.

Cutler Group first reported a position in JAZZ in Q4 2015 and held it in 18 quarters. The position peaked at $1.62M in Q4 2015. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • Cutler Group reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 100 Jazz Pharmaceuticals shares in Q1 2023, an estimated $15K.
  • Cutler Group first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 18 quarters.
  • Cutler Group's Jazz Pharmaceuticals position peaked at $1.62M in Q4 2015.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.